Company intelligence / Profile preview

Esfam Biotech

Victoria, Australiaesfambiotech.com.au ↗

Ownership: Private
Development stage: Preclinical

Overview

The company has discovered molecules that block SARS-CoV-2 virus from damaging infected cells (confirmed in cell-based studies and animal models), molecules that block PRRS virus binding site in cell-based assays, and revealed anti-cancer effects in cell and animal models against prostate cancers that don't respond to hormone blockade[1][2]

Therapeutic areas: OncologyInfectious Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

delcetravir

Phase 1

Indications: COVID-19

Beyond the preview

Go deeper on Esfam Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Esfam Biotech.

Explore the full profile